Blood pressure and diabetes: Vicious twins

Heart

Volumn 99, Issue 8, 2013, Pages 577-585

  Chokshi, Neel P ^a   Grossman, Ehud ^b   Messerli, Franz H ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; RENIN INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CORONARY ARTERY CALCIFICATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FRAMINGHAM RISK SCORE; GOUT; GYNECOMASTIA; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPONATREMIA; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY DENERVATION; KIDNEY DISEASE; KIDNEY FAILURE; KINESIOTHERAPY; LOW DRUG DOSE; MICROALBUMINURIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; SODIUM RESTRICTION; SYSTOLIC HYPERTENSION; TACHYCARDIA; WEIGHT REDUCTION;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; HUMANS; HYPERTENSION; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84875258011     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302029     Document Type: Article

References (20)

1. Schramm TK, Gislason GH, Kober L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008;117:1945-54. (Pubitemid 351543470)
2. Chen G, McAlister FA, Walker RL, et al. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension 2011;57:891-7. This study emphasises the additional risk of HTN in diabetic patients.
3. Brown MJ, Castaigne A, de Leeuw PW, et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000;35:1038-42. (Pubitemid 30327254)
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.
5. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336-45. This study shows the importance of coronary calcium as a predictor of coronary events. (Pubitemid 351468410)
6. Shemesh J, Motro M, Morag-Koren N, et al. Relation of coronary artery calcium to cardiovascular risk in patients with combined diabetes mellitus and systemic hypertension. Am J Cardiol 2012;109:8446-50. This study shows, with long term follow-up, that diabetic hypertensive patients without coronary calcium are at low cardiovascular risk.
7. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. (Pubitemid 37430158)
8. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85. This prospective study shows that in diabetic hypertensive patients, aggressive lowering of blood pressure does not reduce the risk of cardiovascular events and is associated with increased adverse events.
9. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-8. This retrospective analysis shows that in diabetic hypertensive patients with ischaemic heart disease, aggressive lowering of blood pressure is not associated with improved outcomes.
10. Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation 2011;123:2799-810, 9 p following 810. This meta-analysis shows that in diabetic patients, lowering blood pressure to below 130/80 mm Hg reduces the rate of stroke but not of other cardiovascular events and is associated with adverse events. The authors demonstrate that in diabetic patients a target blood pressure of below 135/85 mm Hg may be acceptable.
11. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
12. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59. This prospective study shows that the combination of ACE inhibitor and ARB does not reduce the primary end points more than the ACE inhibitor alone and is associated with greater adverse events. (Pubitemid 351522739)
13. Grossman E, Messerli FH. Are calcium antagonists beneficial in diabetic patients with hypertension? Am J Med 2004;116:44-9. (Pubitemid 38050026)
14. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28. This prospective study shows that the combination of an ACE inhibitor with amlodipine is superior to the combination of ACE inhibitor and thiazide.
15. Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-62. (Pubitemid 47498283)
16. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401-9. (Pubitemid 40973423)
17. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45. (Pubitemid 351664214)
18. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009;20:2641-50. This study shows that the addition of spironolactone, but not losartan, to a regimen including maximal ACE inhibition affords greater renoprotection in diabetic nephropathy despite a similar effect on BP.
19. Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010;56:77-85.
20. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 2010;376:1903-9. This prospective study on a small group of patients with resistant HTN shows the blood pressure lowering effect of renal nerve denervation.